Associations of genetic variants in ATP-binding cassette A1 and cholesteryl ester transfer protein and differences in lipoprotein subclasses in the Multi-Ethnic Study of Atherosclerosis

Clinical Chemistry

Volumn 55, Issue 3, 2009, Pages 481-488

  Tsai, Michael Y ^a,j   Li, Na ^b   Sharrett, A Richey ^c   Shea, Steven ^d   Jacobs Jr , David R ^e,f   Tracy, Russell ^g   Arnett, Donna ^h   Arends, Valerie ^a   Post, Wendy ^c,i  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Mayo Mail Code 609   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ABC TRANSPORTER;

ADULT; AGED; ALLELE; ARTICLE; ASSAY; ATHEROSCLEROSIS; BIOCHEMISTRY; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART PROTECTION; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL ESTER TRANSFER PROTEINS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 62149116040     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.107995     Document Type: Article

References (38)

1. Cholesterol Treatment Trialists' (CTT) Collabora- tors. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Cholesterol Treatment Trialists' (CTT) Collabora- tors. Efficacy of cholesterol-lowering treatment in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-25.
3. Charlton-Menys V, Durrington PN. Human choles- terol metabolism and therapeutic molecules. Exp Physiol 2008;93:27-42.
4. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
5. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr. Association of coro- nary atherosclerosis with hyperapobetalipopro- teinemia [increased protein but normal choles- terol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A 1980;77: 604-8.
6. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Kauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarc- tion. JAMA 1988;260:1917-21.
7. Griffin BA, Minihane AM, Furlonger N, Chap- man C, Murphy M, Williams D, et al. Inter- relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci (Lond) 1999;97:269-76.
8. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Junger I, Walldius G. Apo- lipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003;361:777-80.
9. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas MC, Chapman MJ, Couture P, et al. Apo B versus cholesterol to estimate cardiovascular risk and to guide therapy: report of the Thirty Person/Ten Country Panel. J Intern Med 2006; 259:247-58.
10. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apoli- poprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92.
11. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776-85.
12. Van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007; 146:640-8.
13. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk. Diabetes Care 2008;31:811-21.
14. Stein EA, Sniderman A, Laskarzewski P. Assess- ment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein choles- terol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005;96(9 Suppl 1):36K-43K.
15. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clarke L, Hunninghake DB, et al., for the Co-ordinating Committee of the National Choles- terol Education Program. Implications of recent clinical trials for the National Cholesterol Educa- tion Program Adult Treatment Panel III Guide- lines. Circulation 2004;110:227-39.
16. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46:733-49.
17. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27: 1496-504.
18. Colhoun HM, Thomason MJ, Mackness MI, Ma- ton SM, Betteridge DJ, Durrington PN, et al., and the CARDS Investigators. Design of the Collabo- rative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19:201-11.
19. Colhoun HM, Betteridge DJ, Durrington PN, Hit- man GA, Neil HAW, Livingstone SJ, et al., on behalf of the CARDS Investigators. Primary pre- vention of cardiovascular disease with atorvasta- tin in type 2 diabetes in the Collaborative Ator- vastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-96.
20. Colhoun H, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Rapid emer- gence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Dia- betes Study (CARDS). Diabetologia 2005;48: 2482-5.
21. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standard- ization project for measurements of apolipopro- teins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992; 38:658-62.
22. Warnick GR, Albers JJ. A comprehensive evalua- tion of the heparin-manganese precipitation pro- cedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
23. Friedewald WT, Levy RI, Frederickson DS. Estima- tion of the concentration of low-density lipopro- tein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
24. Warnick GR, Nauck M, Rifai N. Evolution of meth- ods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001;47:1579-96.
25. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al., and the Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guide- lines on cardiovascular disease prevention in clin- ical practice: executive summary. Atherosclerosis 2007;194:1-45.
26. McElduff P, Jaefarnezhad M, Durrington P. Amer- ican, British and European recommendations for statins in the primary prevention of cardiovascu- lar disease applied to British men studied pro- spectively. Heart 2006;92:1213-8.
27. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, for the ACCESS Study Group. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5-hydroxymethylglu- taryl coenzyme A reductase inhibitors on non- high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265-9.
28. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13:170-89.
29. Franceschini G, Cassinotti M, Vecchio G, Gian- franceschi G, Pazzucconi F, Murakami T, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without chang- ing LDL subclass pattern. Arterioscler Thromb 1994;14:1569-75.
30. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ. Dose-dependent ac- tion of atorvastatin in type IIb hyperlipidaemia: preferential and progressive reduction of athero- genic apo B-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002; 163:287-96.
31. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, et al, and the CARDS investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein sub- classes in type 2 diabetic patients with isch- aemic heart disease. Atherosclerosis 2003;167: 243-55.
32. Caslake MJ, Stewart G, Day SP, Daly E, McTag- gart F, Chapman MJ, et al. Phenotype-dependent and independent action of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipi- daemia. Atherosclerosis 2003;171:245-53.
33. Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Int J Car- diol 2005;104:338-45.
34. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor- mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia het- erozygotes. Proc Natl Acad Sci U S A 1983;80: 4124-8.
35. Grundy SM, Vega GL. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 1985; 26:1464-75.
36. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and par- ticle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochem- istry 1998;37:12867-74.
37. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Boulton AJ. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density lipoproteins in patients with non-insulin dependent diabetes mellitus. Diabet Med 1996;13:139-44.
38. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in com- bined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20:189-97.